Page 35 - Ipid Management News Today

Lipid and fatty acid traits may be implicated in early Alzheimers disease, and could signal treatment targets.

An investigational antisense oligonucleotide drug targeting a novel cholesterol pathway showed disappointing results in this phase 2b study.

They include new generalist-friendly labels for the traditional but obscurely named four stages of HF that, it is hoped, will have wider reach and expand the use of effective therapies.

The results add to growing enthusiasm for achieving the holy grail of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.

Trial results for the twincretin in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.

Meeting guideline-recommended exercise targets lowers risk of CVD in everyone, but even more so in patients with anxiety or depression, new research shows.

The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed.

Many claims have been made about the health benefits of omega-3 fatty acids. A review of the data, however, does not support many benefits, and even suggests potential risks.

The multiverse exists as the ACC offers a traditional in-person meeting spanning all of cardiology paired with what could be a lasting legacy of the pandemic, a robust, parallel virtual experience.

A new analysis suggests all levels of alcohol intake are harmful with regard to cardiovascular disease, and the risk increases exponentially as alcohol intake rises, even at moderate levels.